Response to treatment of cutaneous leishmaniasis with intralesional chloroquine vs intralesional meglumine antimoniate
Keywords:
Cutaneous leishmaniasis, intralesional, chloroquine, meglumine antimoniateAbstract
Background In Pakistan, cutaneous leishmaniasis (CL) is mostly caused by Leishmania major. For simple lesions which are few in number and where there is no risk of disfigurement or joint mobility restriction, topical application or local treatment e.g. intralesional antimony compounds are valuable. Objective To compare the effect of intralesional chloroquine with meglumine antimoniate in the treatment of CL. Patients and methods Patients and methods In this quasi experimental study, 60 patients of CL with 1 to 3 lesions and aged >3years were divided into 2 treatment groups to receive either intralesional chloroquine (treatment group) or meglumine antimoniate (control group). Both drugs were used 1cc per cm2 of lesion, once weekly for 8 weeks (8 injections). 8 more injections were given to those who showed partial response. Results Both treatments showed 100% response; however, greater number of injections was required with meglumine antimoniate (p<0.05). Both drugs were well tolerated. Conclusion Intralesional chloroquine appears to be an effective, safe and cheap alternative to meglumine antimoniate in the treatment of CL.References
Vega-Lopez F, Hay RJ. Leishmaniasis. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology. London: Blackwell Science; 2004. p. 32:32-35-47.
Magill AJ. Leishmaniasis. In: Hunter GW, Strickland GT, eds. Hunter's Tropical Medicine and Emerging Infectious Diseases. 8th ed. Philadelphia: WB Saunders; 2000. P. 665-87.
Dedet JP, Pratlong F. Leishmaniasis. In: Manson P, Cook GC, Zumla A, eds. Manson's Tropical Disease. 21st edn. London: WB Saunders; 2003. p. 1339-64.
World Health Organization (WHO): Weekly epidemiological record No. 44. Vol 77. 2002; 365-372.
Bhutto AM, Soomro RA, Nonaka S, Hashiguchi Y. Detection of new endemic areas of cutaneous leishmaniasis in Pakistan: a 6-year study. Int J Dermatol 2003; 42: 543-8.
Ayub S, Gramiccia M, Khalid M et al. Cutaneous leishmaniasis in Multan: species identification. J Pak Med Assoc 2003; 53: 445-7.
Jaffernay M, Nighat R. Cutaneous leishmaniasis in Pakistan. Int J Dermatol 2001; 40: 159.
Kolaczinski J, Brooker S, Reyburn H, Rowland M. Epidemiology of anthroponotic cutaneous leishmaniasis in Afghan refugee camps in northwest Pakistan. Trans R Soc Trop Med Hyg 2004; 98: 373-8.
Rahman S, Bari A. Laboratory profile in patients of cutaneous leishmaniasis from various regions of Pakistan. J Coll Physicians Surg Pak 2003; 13: 313-6.
Rogers ME, Ilg T, Nikolaev AV et al. Transmission of cutaneous leishmaniasis by sandflies is enhanced by regurgitation of fPPG. Nature 2004; 430: 463-7.
Iftikhar N, Bari I, Ejaz A. Rare variants of cutaneous leishmaniasis: whitlow, paronychia, and sporotrichoid. Int J Dermatol 2003; 42: 807-9.
Paredes R, Munoz J, Diaz I et al. Leishmaniasis in HIV infection. J Postgrad Med 2003;49:39-49.
Tierney LM, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis & Treatment 2005, 44th edn. New York: McGraw-Hill; 2004.
Faber WR, Oskam L, van Gool T et al. Value of diagnostic techniques for cutaneous leishmaniasis. J Am Acad Dermatol 2003; 49: 70-4.
Esfandiarpour, Alavi A. Evaluating the efficacy of allopurinol and meglumine antimonite (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 2002; 41: 521-4.
ZvulunovA, Klaus S, Vardy D et al. Fluconazole for the treatment of cutaneous leishmaniasis. N Engl J Med 2002; 347: 370-1.
Alrajhi AA, Ibrahim EA, Devol EB et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346: 891-5.
Soto J, Toledo J, Gutierrez P et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33: e57-61.
Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739-46.
Lee SA, Hasbun R. Therapy of cutaneous leishmaniasis. Int J Infect Dis 2003; 7: 86-93.
Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis: new approaches to disease control. BMJ 2003; 326: 377-82.
Gurei MS, Tatli N, Ozbilge H et al. Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol 2000; 30: 169-76.
Noor SM, Hussain D. Intralesional chloroquine in cutaneous leishmaniasis. J Pak Assoc Dermatol 2005; 15: 18-21.
Arevalo I, Ward B, Miller R et al. Successful treatment of drug resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33: 1847-51.
KroegerA, Avila EV, Morison L. Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: Cluster randomized trial. BMJ 2002; 325: 810-3.
